← All trials
NCT06650514
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Jun 30, 2026
- Completion date
- Dec 31, 2026
- First posted
- Oct 21, 2024
- Last posted
- Oct 21, 2024
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidad Autonoma de BarcelonaLead sponsor
- Osteosarcoma InstituteCollaborator
- Memorial Sloan-Kettering Cancer CenterCollaborator
- Peptomyc S.L.Collaborator
- Oregon Health and Science UniversityCollaborator
- Harvard UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.